The Vaccine Integrity Project (VIP) at the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) is gearing up for its next big task: reviewing the data surrounding the birth dose of the hepatitis B vaccine. This move comes as federal vaccine advisors consider altering their guidance on when children should receive the hepatitis B vaccine, raising questions about the need for a new recommendation. The VIP's review aims to shed light on the decades-long safety, efficacy, and public health impact of administering the hepatitis B shot at birth, a policy recommended by the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) since 1991. Since the universal birth dose policy was adopted, hepatitis B infections in the United States have declined by an impressive 95%. But here's where it gets controversial... The Advisory Committee on Immunization Practices (ACIP) at the CDC recently tabled a vote on whether to recommend delaying the hepatitis B shot for a month if the mother tests negative for the virus. This decision has sparked debate, with some ACIP members questioning the data on the safety and efficacy of the birth dose, while others are cautious about changing the recommendation without new data. The VIP's review will draw upon ACIP's prior Evidence-to-Recommendation (EtR) analyses, CDC surveillance data, published epidemiologic studies, systematic reviews, and reports from the AAP and other professional medical organizations. The goal is to provide clarity and ensure that any changes to the recommendation are grounded in the strongest possible science. So, what do you think? Is a new recommendation needed? Share your thoughts in the comments below and let's keep the conversation going!
